share_log

10-Q: Q1 2024 Earnings Report

10-Q: Q1 2024 Earnings Report

10-Q:2024財年一季報
美股SEC公告 ·  05/08 19:53

牛牛AI助理已提取核心訊息

Clene Inc. (Clene) reported a net loss of $11.08 million for the first quarter ended March 31, 2024, a slight improvement from the $11.77 million loss in the same period last year. The basic and diluted net loss per share for common stockholders was $0.09, compared to $0.15 in the previous year. Revenue from related parties, including product and royalty revenue, totaled $72,000, a decrease from $106,000 year-on-year. Operating expenses saw a 14% reduction, with research and development expenses decreasing by 21% to $5.869 million. General and administrative expenses remained relatively stable at $3.420 million. Clene's business development included an amended agreement with 4Life, granting exclusive rights to purchase and sell certain Clene products, with a minimum sales commitment extending through 2033. The company also entered a subaward under the NIH...Show More
Clene Inc. (Clene) reported a net loss of $11.08 million for the first quarter ended March 31, 2024, a slight improvement from the $11.77 million loss in the same period last year. The basic and diluted net loss per share for common stockholders was $0.09, compared to $0.15 in the previous year. Revenue from related parties, including product and royalty revenue, totaled $72,000, a decrease from $106,000 year-on-year. Operating expenses saw a 14% reduction, with research and development expenses decreasing by 21% to $5.869 million. General and administrative expenses remained relatively stable at $3.420 million. Clene's business development included an amended agreement with 4Life, granting exclusive rights to purchase and sell certain Clene products, with a minimum sales commitment extending through 2033. The company also entered a subaward under the NIH Grant to support an Expanded Access Program for CNM-Au8 treatment of ALS, with potential subawards totaling up to $30.9 million. Clene's future plans involve initiating an international Phase 3 trial for CNM-Au8 in ALS and continuing clinical trials for multiple sclerosis. The company's financial overview highlighted the need for additional capital to sustain operations, with a focus on equity financing, debt financing, and licensing or collaboration arrangements.
Clene公司(Clene)報告稱,截至2024年3月31日結束的第一季度淨虧損爲1108萬美元,相較於上一年同期的1177萬美元虧損有所改善。普通股股東每股基本和稀釋淨虧損爲0.09美元,去年同期爲0.15美元。來自關聯方的收入,包括產品和版稅收入,總額爲72,000美元,同比下降了106,000美元。營業費用減少了14%,其中研發費用減少了21%至586.9萬元。總務和行政費用保持相對穩定,爲342萬元。Clene的業務發展包括與4Life的修訂協議,授予其購買和銷售某些Clene產品的獨家權利,最低銷售承諾延長到2033年。該公司還進入了NIH Grant的子獎項,以支持ALS的CNm-Au8治療的擴大使用計劃,潛在子獎項總額高達3090萬元。Clene未來的計劃包括在ALS中啓動CNm-Au8的國際3期試驗,並繼續進行多發性硬化的臨床試驗。公司的財務概述強調了需要額外資本來維持運營,重點關注股權融資,債務融資和許可或合作安排。
Clene公司(Clene)報告稱,截至2024年3月31日結束的第一季度淨虧損爲1108萬美元,相較於上一年同期的1177萬美元虧損有所改善。普通股股東每股基本和稀釋淨虧損爲0.09美元,去年同期爲0.15美元。來自關聯方的收入,包括產品和版稅收入,總額爲72,000美元,同比下降了106,000美元。營業費用減少了14%,其中研發費用減少了21%至586.9萬元。總務和行政費用保持相對穩定,爲342萬元。Clene的業務發展包括與4Life的修訂協議,授予其購買和銷售某些Clene產品的獨家權利,最低銷售承諾延長到2033年。該公司還進入了NIH Grant的子獎項,以支持ALS的CNm-Au8治療的擴大使用計劃,潛在子獎項總額高達3090萬元。Clene未來的計劃包括在ALS中啓動CNm-Au8的國際3期試驗,並繼續進行多發性硬化的臨床試驗。公司的財務概述強調了需要額外資本來維持運營,重點關注股權融資,債務融資和許可或合作安排。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。